AI Article Synopsis
- Neutralizing antibody (NAb) titer is crucial for measuring protection against SARS-CoV-2 infection, but current testing methods are not widely accessible.
- A new lateral flow assay has been developed that measures the amount of neutralized SARS-CoV-2 receptor-binding domain (RBD) that no longer binds to ACE2, showing a strong correlation with NAb titer from vaccinated and recovered patients.
- This testing method outperforms existing techniques and could potentially be used for large-scale assessments of immunity in the population, making it easier for individuals to check their NAb titer at home.
Article Abstract
Neutralizing antibody (NAb) titer is a key biomarker of protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but point-of-care methods for assessing NAb titer are not widely available. Here, we present a lateral flow assay that captures SARS-CoV-2 receptor-binding domain (RBD) that has been neutralized from binding angiotensin-converting enzyme 2 (ACE2). Quantification of neutralized RBD in this assay correlates with NAb titer from vaccinated and convalescent patients. This methodology demonstrated superior performance in assessing NAb titer compared with either measurement of total anti-spike immunoglobulin G titer or quantification of the absolute reduction in binding between ACE2 and RBD. Our testing platform has the potential for mass deployment to aid in determining at population scale the degree of protective immunity individuals may have following SARS-CoV-2 vaccination or infection and can enable simple at-home assessment of NAb titer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350670 | PMC |
| http://dx.doi.org/10.1016/j.crmeth.2022.100273 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!